An open-label, multicenter, phase II study to evaluate the safety and efficacy of BB-1701, a novel antibody drug conjugate (ADC) targeting HER2, in previously treated patients (pts) with HER2+or HER2-low unresectable or metastatic (M) breast cancer (BC) Meeting Abstract
| Authors: | George, M.; Frenel, J. S.; CorteĢs, J.; Schmidt, M.; Saenz, J. A. G.; Blau, S.; Abdulla, N. E.; Nishimura, M.; Sakai, H.; Babu, S.; McAndrew, N. P.; Ali, A.; Pavic, M.; Jhaveri, K.; Jones, J. M.; Rugo, H. S.; Mody, K.; Smith, A. D.; Yamashita, T. |
| Abstract Title: | An open-label, multicenter, phase II study to evaluate the safety and efficacy of BB-1701, a novel antibody drug conjugate (ADC) targeting HER2, in previously treated patients (pts) with HER2+or HER2-low unresectable or metastatic (M) breast cancer (BC) |
| Meeting Title: | ESMO Congress 2024 |
| Journal Title: | Annals of Oncology |
| Volume: | 35 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2024 Sept 13-17 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2024-09-01 |
| Start Page: | S404 |
| Language: | English |
| ACCESSION: | WOS:001326612900432 |
| DOI: | 10.1016/j.annonc.2024.08.384 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 437TiP -- Source: Wos |
